Rift Valley fever phlebovirus Nucleocapsid Protein (RVFV-NP)

Product Specifications

Background

Rift Valley fever (RVF) is a mosquito-borne viral zoonosis that was first discovered in Kenya in 1930 and is now endemic throughout multiple African countries and the Arabian Peninsula. RVF virus primarily infects domestic livestock (sheep, goats, cattle) causing high rates of neonatal mortality and abortion, with human infection resulting in a wide variety of clinical outcomes, ranging from self-limiting febrile illness to life-threatening haemorrhagic diatheses, and miscarriage in pregnant women. Since its discovery, RVF has caused many outbreaks in Africa and the Arabian Peninsula with major impacts on human and animal health. However, options for the control of RVF outbreaks are limited by the lack of licensed human vaccines or therapeutics.

Structure Composition

Inclusion body;0.5mol Urea, PH=8

Swiss Prot

DQ380154.1

Reactivity

E. coli Expression

Applications

Reseach

Dilution

Reseach

Purity

Transferred into competent cells and the supernatant was purified by NI column affinity chromatography and the purity is > 85% (by SDS-PAGE) .

Molecular Weight

735bp;27kDa

Storage Conditions

Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze-thaw cycles.

Notes

For research use only, not for use in diagnostic procedure.

Specificity

Carrier:pET30a-RVFV-NP-His (C-term) Virus:Rift Valley fever virus strain MP-12 segment S, complete sequence

Host or Source

His-tag

Control Type

Rift Valley fever phlebovirus Nucleocapsid Protein, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained overnight with Coomassie Blue. The purity of the protein is greater than 85%.